Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report)’s stock price hit a new 52-week low during trading on Tuesday after Wedbush downgraded the stock from a hold rating to a strong sell rating. The company traded as low as $30.01 and last traded at $32.63, with a volume of 94961 shares trading hands. The stock had previously closed at $33.55.
Other equities research analysts have also recently issued research reports about the company. HC Wainwright lowered their target price on Praxis Precision Medicines from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Monday. Deutsche Bank Aktiengesellschaft began coverage on Praxis Precision Medicines in a report on Tuesday, February 11th. They set a “buy” rating and a $111.00 target price on the stock. Truist Financial decreased their price objective on Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating on the stock in a report on Monday. Oppenheimer raised their price objective on Praxis Precision Medicines from $143.00 to $163.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, Robert W. Baird decreased their price objective on Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating on the stock in a report on Monday. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Praxis Precision Medicines presently has an average rating of “Moderate Buy” and a consensus price target of $123.80.
Get Our Latest Analysis on PRAX
Institutional Inflows and Outflows
Praxis Precision Medicines Trading Up 7.9 %
The firm has a market capitalization of $674.88 million, a PE ratio of -3.52 and a beta of 2.65. The firm has a 50-day moving average of $74.53 and a two-hundred day moving average of $69.53.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($2.76) by ($0.18). Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%. The firm had revenue of $7.48 million during the quarter, compared to analysts’ expectations of $0.36 million. Equities research analysts expect that Praxis Precision Medicines, Inc. will post -10.22 earnings per share for the current fiscal year.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Read More
- Five stocks we like better than Praxis Precision Medicines
- How to Choose Top Rated Stocks
- GitLab: Get In While It’s Down—Big Rebound Ahead
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Tesla Stock: Finding a Bottom May Take Time
- Top Biotech Stocks: Exploring Innovation Opportunities
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.